• BridgeBio Pharma has released previously announced positive Phase 3 PROPEL 3 data for oral infigratinib in children with achondroplasia, now published in the New England Journal of Medicine, showing statistically significant gains in annualized height velocity, body proportionality and arm span with a favorable safety profile.
• The company now plans to file regulatory applications in the US and EU starting in the third quarter of 2026, positioning oral infigratinib as a potential first approved oral therapy targeting the underlying FGFR3 pathway in achondroplasia and related skeletal dysplasias.
• We’ll now examine how NEJM-published PROPEL 3 data and planned infigratinib regulatory filings might reshape BridgeBio’s rare disease investment narrative.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

BridgeBio Pharma Investment Narrative Recap

To own BridgeBio today, you need to believe that Attruby can keep funding a growing rare disease franchise while late stage programs like infigratinib and BBP‑418 broaden the portfolio and reduce single‑drug dependence. The NEJM PROPEL 3 data strengthens the case that infigratinib could become a meaningful second growth pillar, but it does not change the near term reality that the biggest catalyst is upcoming regulatory decisions across the late stage pipeline, nor the key risk of continued high cash burn and potential dilution.

Among the recent announcements, BridgeBio’s addition to multiple Russell indexes, including the Russell 1000 and Russell Midcap, stands out in the context of the PROPEL 3 news. Index inclusion can increase visibility and index fund ownership just as the infigratinib program moves toward planned US and EU filings starting in 2026, potentially amplifying investor focus on how successfully BridgeBio can convert late stage pipeline momentum into a more diversified revenue base.

Yet while infigratinib strengthens the long term story, investors should also be aware that BridgeBio’s dependence on Attruby and ongoing losses mean...

BridgeBio Pharma's narrative projects $2.7 billion revenue and $895.2 million earnings by 2029.

Uncover how BridgeBio Pharma's forecasts yield a $102.71 fair value, a 38% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming BridgeBio might still be unprofitable in three years even with revenue growing about 57% annually, so if you are weighing PROPEL 3 and future filings, it is worth comparing that more cautious view with your own expectations.

Explore 7 other fair value estimates on BridgeBio Pharma - why the stock might be worth less than half the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your BridgeBio Pharma research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free BridgeBio Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BridgeBio Pharma's overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.